BioSpace News Archive

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the US Food and Drug Administration has granted Orphan Drug Designation to OTOF-GT, Sensorion’s lead gene therapy program, intended for the treatment of otoferlin gene mediated hearing loss.

AGIC Capital, a growth-oriented private equity firm with $2.2 billion of assets under management, announced that it had acquired a majority stake in ATEC Pharmatechnik GmbH.

Clover Biopharmaceuticals, Ltd. and the International Vaccine Institute announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

The University of Aizu collaborated on development of the technology designed to help verify individuals’ identity and protect data integrity.

Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares (“Shares”) of Akouos’s common stock in exchange for (a) $12.50 per Share.

Optinose today provided corporate updates and announced that CEO Peter Miller will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022.

Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeline to focus on its lead viral RNA (vRNA) immunotherapy product candidate, ONCR-021.

HOOKIPA Pharma Inc. today announced that the company will participate virtually in investor meetings and panel discussions at The JMP Securities Hematology and Oncology Summit, December 6 - 7, 2022.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it has submitted an exploratory Investigational New Drug (eIND) application to the U.S. Food and Drug Administration (FDA) for a planned First-in-Human Phase 0 clinical trial.

Aridis Pharmaceuticals, Inc. today announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a clinical trial of AR-501 in cystic fibrosis (CF) patients.